{"text_format":"3","workbook":"xls","n_sheets":1,"sheets":["FinalFile_Supplemental_INQ-5151"],"not_rendered":{"external_links":1,"defined_names":3},"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"FinalFile_Supplemental_INQ-5151","index":0,"n_rows":9,"n_cols":6,"rows_kept":9,"merged":[[1,0,2,0],[1,1,1,2],[1,3,1,4],[1,5,2,5],[8,0,8,5]],"flags":["formulas_cached_only"]}
["Table S1 Subsequent chemotherapy"]
["Treatment","nab-PTX plus RAM",null,"PTX plus RAM",null,"P value"]
[null,"N = 113","%","N = 138","%"]
["PD-1/PD-L1 inhibitor",65,57.5,37,26.8,"< 0.001 "]
["Irinotecan",36,31.9,65,47.1,0.014]
["Platinum re-challenge",8,7.1,25,18.1,0.01]
["Clinical trials",41,36.3,33,23.9,0.032]
["Any [A2] subsequent therapies",85,75.2,80,58,0.004]
["nab-PTX, nanoparticle albumin-bound paclitaxel; RAM, ramucirumab; PD-1, programmed cell death 1; programmed cell death 1 ligand 1"]